cyrilzakka/clinical-trials huggingface dataset:
Factors Associated With Coronary Heart Disease in African Americans in the Jackson Heart Study

Coronary heart disease (CHD) is the leading cause of deaths that are related to cardiovascular disease in the United States, and Mississippi's CHD mortality rate is the highest in the nation. This study will examine data from the Jackson Heart Study to determine the effect of socioeconomic status and psychosocial factors on CHD risk in African Americans in Mississippi.

CHD is a disease that is characterized by narrowing of the coronary arteries that supply blood to the heart. As a result, insufficient amounts of oxygen and nutrients reach the heart, which can cause chest pain or heart attack. Studies have shown that people's socioeconomic status is associated with their health, and that African Americans experience the highest rates of heart disease in the U.S. The Jackson Heart Study (JHS) is currently being conducted in Jackson, Mississippi, and is studying the factors that influence the development of cardiovascular disease in African American men and women. This study will examine data from the JHS to determine the effect of socioeconomic status and psychosocial factors on CHD risk in African Americans in Mississippi.

This study will recruit participants from the JHS only. Participants will report to the study site at least once for 4.5 hours for baseline measurements. Visits will include measurements of body size and blood pressure, an electrocardiogram, an echocardiogram, an ultrasound of the carotid artery, blood and urine collection, a lung function test, and interviews regarding health status and sociocultural aspects of life. Follow-up evaluations will occur 5 and 10 years after starting the study. Outcomes will include self-report and electrocardiogram-defined CHD, as well as measures of various social and psychological factors.

Eligibility Criteria:
Inclusion Criteria:

* Participant in the Jackson Heart Study
* Diagnosis of coronary heart disease

Exclusion Criteria:

* N/A
Comparative Study Between Biodentine and Mineral Trioxide Aggregate in Direct Pulp Capping

Comparative study between Biodentine and MTA in direct pulp capping of deeply carious teeth.


Eligibility Criteria:
Inclusion Criteria:

1. asymptomatic vital molars (upper or lower)
2. with complete formation of roots
3. Aged 15 to 30 years.
4. Accidental point pulp exposure during the process of removing dental caries.

Exclusion Criteria:

1. If the molar not vital.
2. If the molar is symptomatic.
3. Immature molar.
4. Patient not in age between (15-30 years).
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC

A Randomized, Double-Blind, Multi-Center Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody Injection) + Serplulimab (HLX10, Recombinant Anti-PD-1 Humanized Monoclonal Antibody) +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)


Eligibility Criteria:
Inclusion Criteria:

1. Voluntarily participate in the clinical study; fully understand, be informed about the study, and have signed the informed consent form (ICF); be willing to follow and be able to complete all trial procedures.
2. Males or females aged ≥ 18 years at the time of signing the ICF.
3. Histologically or cytologically proven recurrent or metastastic NPC.
4. At least one measurable target lesion is assessed by the IRRC according to the RECIST v1.1 within 4 weeks prior to randomization.
5. An ECOG performance status score of 0-1 within 7 days prior to the first dose of the investigational product.
6. An expected survival period ≥ 12 weeks.

Exclusion Criteria:

1. Other active malignancies within 3 years prior to the first dose of investigational product. Localized tumors that have been cured such as superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ, and breast cancer in situ are acceptable.
2. Patients who are going to receive or have received an organ or bone marrow transplant.
3. With uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage (monthly or more frequently).
4. With cerebrovascular accident, myocardial infarction, unstable angina, poorly controlled arrhythmia (including QTc intervals ≥ 450 ms for males and ≥ 470 ms for females) (QTc intervals are calculated by Fridericia formula) within half a year.
5. Class III to IV cardiac insufficiency according to New York Heart Association (NYHA) classification (Appendix 5) or an LVEF (left ventricular ejection fraction) \< 50% by cardiac color Doppler.
6. Inadequately controlled hypertension (systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg).
7. With human immunodeficiency virus (HIV) infection.
Evaluating Treatment Response in Laryngo-Pharyngeal Reflux

Although laryno-pharyngeal reflux (LPR) and gastroesophageal reflux disease (GERD) differ in symptoms and treatment, they are diagnosed by the same standard 24-hour pH monitoring system which measures liquid reflux in the esophagus. The investigators are evaluating a new 24-hour pharyngeal pH monitoring system by Restech which can measure acid exposure in the airway and can be used specifically for LPR diagnosis. The purpose of this study is to determine whether the Restech device is more effective than standard pH monitoring in predicting the response to proton pump inhibitor (PPI) acid suppression therapy using Dexlansoprazole in patients with symptoms and/or manifestations of LPR.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 years old or above
* Have a clinical diagnosis of LPR
* Able and willing to provide consent

Exclusion Criteria:

* History of any previous anti-reflux operation or procedure
* History of pharyngeal or laryngeal surgery
* History of larngeal or hypolaryngeal neoplasm
* Allergy or significant adverse reaction to PPI
* Patient on PPI therapy within 4 weeks prior to enrollment
* A cumulative history of PPI therapy equal to or greater than 3 months
* History of noncompliance with medication or study protocols
* Enrolled in another clinical trial using investigational medications
Identification of Time-invariant EEG Signals for Brain-Computer Interface

This study aims to identify various time-variant and time-invariant components of EEG signals using advanced signal processing techniques, such as machine learning. The investigators' ultimate goal is to develop universal or customised brain-computer interface that are stable across days or even years.


Eligibility Criteria:
Exclusion criteria:

1. Severe vision disorders which prevent volunteers to recognize instructions on the screen
2. Severe psychiatric disorders
3. Severe sleep disorders which keep volunteers awake for two hours
4. Volunteers with claustrophobia
5. Patients who underwent stroke and brain surgery
6. Patients with neuromuscular diseases
Graduated Embryo Score (GES) in the Fresh Cycle Predicts Outcome From Frozen Embryo Transfer

Evaluation of embryo quality in the fresh cycle as a predictor of outcome from frozen embryo transfer.

Outcomes from frozen embryo transfer reviewed based on the quality of the embryos in the ftresh cycle as assessed by the Graduatede embryo score.

Eligibility Criteria:
Inclusion Criteria:

* 2 frozen blastocysts
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain

The primary hypothesis is that esmolol and lidocaine, when given without the use of a tourniquet, provide relief of propofol injection pain that is superior to placebo when assessed using the propofol pain scoring tool

The study will include three arms: lidocaine, esmolol, and placebo. Eligible patients will be 18-60 years old, ASA physical status 1-3, and scheduled for an elective surgical procedure. Patients will be randomized to receive lidocaine, esmolol, or placebo. Both the patients and the administering/observing providers will be blinded to the study drug or placebo being administered

Eligibility Criteria:
Inclusion Criteria:

* 18-60 years of age
* ASA 1-3
* Elective surgical procedure

Exclusion Criteria:

* BMI ≥ 45
* Pregnancy
* Requirement for RSI or awake intubation
* Suspected or known difficult airway
* Contraindication to IV in either upper extremity
* Chronic pain syndrome including fibromyalgia
* Use of opioids, NSAIDs, or other analgesics within 24 hours (including preoperative PO Celebrex, Lyrica, Tylenol, etc.)
* Any use of opioids in the past three months
* Significant cardiopulmonary or hepatic dysfunction
* Hypersensitivity to study medications
Quality of Life After Liver Resection

Patients with malignant diseases are increasingly receiving more extensive hepatic resections, with im-proved preoperative and postoperative care leading to a reduced postoperative morbidity and mortality. In this setting, postoperative quality of life may become as important as overall patient survival. In this study we will be investigating the effect of the initial disease for which hepatic resection was carried out on short- and long-term quality of life.

Background: Due to advances in operative methods and perioperative care, mortality and morbidity following major hepatic resection have decreased substantially, making long-term quality of life (QoL) an increasingly prominent issue.

Objectives: We plan on evaluating whether postoperative diagnosis is associated with long-term QoL and health in patients who require hepatic surgery for benign or malignant diseases and how QoL evolves with time.

Method: QoL will be evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 and the liver-specific QLQ-LMC21 module. All patients requiring hepatic surgery aged \>18 years will be included in the study. QoL evaluation is carried out preoperatively and at set intervals postoperatively.

Eligibility Criteria:
Inclusion Criteria:

* Patients with planned liver resection

Exclusion Criteria

* Patients with biopsy of the liver only
* Inability of understanding the questionnaire
Analysis of Muscular Properties in Patients With MFS and EDS

The goal of this observational study is to learn and assess muscle morphological and electromechanical properties in patients affected with Marfan syndrome (MFS) and Ehlers Danlos syndrome (EDS). the main questions it aims to answer are:

* To assess the ability to develop muscle strength;
* Muscle and tendon morphology involved in muscle contractions/relaxation;
* Neuromuscular functionality.

Participants will be take part in the study by performing a test for the assessment of the neuromuscular activity (voluntary muscle contractions) and undergoing a muscle ultrasound for the study of muscles and tendons.

Researchers will compare the two groups with a control group to see potential differences in the morphological and neuromuscular structures of syndromic patients.

MFS, with an autosomal dominant inheritance, can lead to the presence of pathological systemic/syndromic phenotypes. Despite the cardiovascular involvement is responsible for the high mortality and morbidity, the skeletal system and the muscular system also present alterations at the metabolic level.

Like MFS, Ehlers-Danlos Syndrome (EDS) is a rare autosomal dominantly inherited connective tissue disorder. EDS is caused by mutations that cause impaired collagen production, therefore of pathological phenotypes affecting connective tissues such as the integumentary system, the system skeletal system, the cardiovascular system and other organs and tissues. Joint dislocations, musculoskeletal pain, atrophic scarring, and severe scoliosis may occur in patients with EDS.

To date, there are no studies in literature assessing neuromuscular properties in patients with MFS and EDS.

However, the analysis of the musculo-tendon morphological and mechanical properties makes it possible to evaluate the muscle capacity especially in pathological conditions, where the morphology and tendon mechanics are altered, thus providing pivotal information on changes in the contractile capacity of the muscle.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of Marfan syndrome or Ehlers Danlos syndrome currently in follow-up at Cardiovascular Genetic Centre IRCCS Policlinico San Donato;
* Signed informed consent;

Exclusion Criteria:

* Previous muscle-tendon injuries in the lower and/or upper limbs;
* Presence of cardiac pacemaker;
* Epilepsia;
* Presence neurological disorders or circulatory diseases in the lower limbs;
* Pregnancy.
Low vs Standard Local Anesthetics Boluses for Continuous Adductor Canal Block in Total Knee Arthroplasty

To investigate the efficacy of two different regimens of local anesthetic boluses for continuous adductor canal block under ultrasound-guidance in total knee arthroplasty at King Chulalongkorn Memorial Hospital.

Total knee arthroplasty (TKA) is a commonly performed surgical procedure for patients with severe knee osteoarthritis. However, one of the challenges associated with TKA is the significant postoperative pain experienced by patients, which can delay early mobilization and physical therapy. Uncontrolled pain worsens patient outcomes and healthcare costs as it can increase the risk of complications after surgery. Therefore, effective pain management is important for optimizing patient outcomes and promoting a smooth recovery process.Despite the absence of a standardized recommendation for the volume and concentration of bolus administration in continuous adductor canal block (CACB), many previous studies, have demonstrated the efficacy of a high-dose bolus followed by a low-concentration local anesthetic infusion for CACB. However, these trials exhibited differences in the doses and volumes of bolus injection. Therefore, the necessity of high concentration and volume bolus CACB in combination with comprehensive multimodal analgesia and LIA for postoperative pain management in TKA remains uncertain. The aim of this study is to investigate the efficacy of two different regimens of local anesthetic used in boluses for continuous adductor canal block under ultrasound-guidance in total knee arthroplasty at King Chulalongkorn Memorial Hospital.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing TKA aged more than 18 years
* Patients with American Society of Anesthesiologists (ASA) class 1-3
* Patients with body weight index (BMI) 18-40 kg/m2

Exclusion Criteria

* Patient refusal to participate
* Patients with known allergic to medications used in the research protocol
* Patients with contraindications to neuraxial or regional anesthesia, including existing neuropathy or neurological deficits involving the lower extremities, coagulopathy or bleeding diathesis and local skin infections
* Patients with contraindications to NSAIDs such as history of coronary artery bypass graft surgery, congestive heart failure, stroke, gastrointestinal bleedings or ulceration, asthma, hepatic and renal disease, abnormal coagulation, or pregnancy
* Patients with chronic opioid use (opioids have been used daily or almost daily for more than three months or sixty milligrams or more of morphine has been used daily for more than one month) or diagnosed with neuropathic pain
* Patients that are unable to perform preoperative Quantitative sensory testing.
Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia

The definition of Thalassemia Intermedia is not generally accepted and the specific clinical and laboratory characteristics varies between patients. Some patients are blood transfusion dependent and others are occasionally transfused. Also the mutations in the beta globin gene are diverse. Another mutations including mutations in the alfa globin gene and in the xmn1 gene can affect the clinical course of this disease. The purpose of this study is to summarize the characteristics of patients with Thalassemia Intermedia treated at the Pediatric Hematology Unit at the HaEmek Medical Center in Israel

The characteristics that will be recorded from the medical files include: demographic data, included gender and ethnic origin, family history, age at diagnosis, number and frequency of blood transfusions including age of first transfusion and physical examination findings.

The laboratory data included iron metabolism parameters, mutation in the alfa and beta gene and the presence of the xmn1 polymorphism.

Eligibility Criteria:
Inclusion Criteria:

-All patients treated at the Pediatric Hematology Unit

Exclusion Criteria:

* Not enough medical records.
* Patients who refuse to give consent to perform genetic studies will be included in the study but only the retrospective clinical data will be recorded.
[18F]PI-2620 Phase 3 Histopathological Study

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.


Eligibility Criteria:
Inclusion Criteria:

Only subjects who meet all of the following criteria will be eligible for enrollment into the study:

1. Males and females aged 50 years and over
2. Have a projected life expectancy of ≤ 1 year as determined by the investigator (terminal medical condition including but not limited to end-stage dementia, end-stage congestive heart failure, end-stage chronic obstructive pulmonary disease (COPD), or end-stage cancer)
3. Written informed consent obtained from the subject and/or the subject's legally authorized representative (LAR), as applicable, to consent for study procedures and brain donation (consent consistent with the legal requirements of the State in which the subject dies)
4. Can tolerate study procedures including lying down in PET scanner. The investigator will carefully assess each subject and use medical judgment to determine whether the subject can tolerate the imaging procedure

Exclusion Criteria:

Subjects will be excluded from the enrollment if they:

1. Are receiving aggressive treatment with life sustaining measures (e.g. receiving chemotherapy; palliative chemotherapy is allowed)
2. Are known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment (e.g. lesions are typically \> 2 cm at their greatest extent and may include stroke, primary or metastatic neoplasm, other tumors or cystic lesions. Subjects with a history of major stroke or traumatic brain injury or other structural lesion as well as cases with a history of primary Central Nervous System (CNS) neoplasm or known metastatic cancer must be discussed with the study sponsor prior to enrollment)
3. Have suspected encephalopathy due to alcoholism or end-stage liver disease
4. Are known to have a Glomerular Filtration Rate below \< 15 mL/min
5. Have received an investigational or approved therapy directly targeting amyloid or tau
6. Are females of childbearing potential who are pregnant, lactating or breastfeeding, or who are not using adequate contraception
7. Have implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI (in case an MRI is planned to be performed)
Resynchronization of Left Ventricular Contraction After Reimplantation of Anomalous Left Coronary Artery

Spontaneous resynchronization of dyskinetic segments of the left ventricle occurs after coronary bypass surgery in adults and has been shown in some children. It is, however, unknown what degree of dyskinesis is likely to be reversible in infants with ischemia from anomalous coronary arteries and what criteria would indicate that a resynchronization strategy of biventricular pacing might be needed.

These questions need data from quantitative serial tissue Doppler observations of patients from pre-operative to late post-operative follow-up.

We have previously studied, at Children's Healthcare of Atlanta, Egleston Hospital, 2 patients with ALCAPA and one other patient is currently enrolled in a prospective study after recent surgery, also at Children's Healthcare of Atlanta. We propose to study these 3 patients with this rare defect concurrently with their routine echocardiographic evaluations. Data will then be taken off-line for analysis.

Standard deviations of times to peak contraction velocity will be assessed for twelve cardiac segments. These will be reevaluated at follow up intervals after surgery on previously obtained echocardiograms. Those subjects in whom improvement of cardiac function, Left Ventricular Ejection Fraction (LVEF) and mitral regurgitation is seen will be compared to those in whom no improvement occurs.

Eligibility Criteria:
Inclusion Criteria:

* Re-implantation of an anomalous left coronary artery from the pulmonary artery

Exclusion Criteria:

* those patients who do not meet inclusion criteria
Diagnosis and Treatment Strategy Optimization of Severe Pneumonia Based on Multi-omics Data Integration

Severe community-acquired pneumonia still has a high incidence and mortality, but the molecular mechanism and prognostic biomarkers of severe community-acquired pneumonia caused by different pathogens are still unclear, and the best treatment strategy has not been determined. Based on this, this project intends to take patients with severe community-acquired pneumonia caused by different pathogens as the research object, explore the molecular mechanism of severe community-acquired pneumonia from multiple angles, integrate relevant research data to evaluate the rationality of initial empirical medication, and lay the foundation for precise treatment of severe pneumonia. The research results will help to develop a new rapid and accurate target for clinical diagnosis and efficacy evaluation of severe pneumonia, and build a precise treatment system for severe pneumonia.


Eligibility Criteria:
Inclusion Criteria:

Age\> 18 years old

Clinical diagnosis of community-acquired pneumonia

Exclusion Criteria:

Pregnancy, perinatal and lactating women

Combined immunosuppressive diseases: such as HIV, solid organ transplantation, solid organ/hematologic malignant tumor chemotherapy, rheumatic diseases or glomerular diseases need to take hormone/immunosuppressant therapy

Combined blood system diseases: such as leukemia reactions, aplastic anemia, neutropenia or deficiency of granulocytes, previous bone marrow/stem cell transplantation
Art Therapy to Treat Women With Fibromyalgia

Effectiveness of an art therapy program for the treatment of pain and improvements in both quality of life and body image of patients with fibromyalgia.

Fibromyalgia (FM) is a chronic non-inflammatory syndrome characterized by diffuse pain throughout the body, sleep disorder, stiffness, fatigue, depression and other psychological problems. Patients with FM feel incapable of performing the majority of activities of daily living. Medication offers only short-term benefits. Thus, it is necessary to include other measures for treatment, such as physical activity and patient education. Art therapy combine the field of psychology with artistic activities, working with therapeutic and instructive aspects as well as the potential for personal growth contained in all forms of art.

Eligibility Criteria:
Inclusion Criteria:

* Classification of fibromyalgia by ACR criteria (Wolf et al, 1990)
* Females
* Without distinction of race
* Age 18 to 65 years
* Do not have changed treatment for fibromyalgia for at least 3meses
* signing the consent form

Exclusion Criteria:

* Other ostearticulares rheumatic and painful
* Decompensated cardio-respiratory diseases
* Perform physical activity more than 2x a week for more than 3 months